Biopharmaceutical giant Gilead Sciences, Inc. (GILD) discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and worldwide.
The company reported impressive sales for the last quarter and raised its full-year guidance. GILD expects total product sales in 2022 to be between $24.5 billion and $25 billion, compared to its previously projected sales in the range of $23.8 billion to $24.3 billion. In addition, GILD expects adjusted earnings per share between $6.35 and $6.75, up from its previous guidance of $6.20 to $6.70.
